Semaglutide helps manage metabolic side effects of antipsychotic drugs

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by certain antipsychotic medications. A randomized trial demonstrated that patients taking this drug experienced weight loss and improved metabolic health compared to those receiving a placebo. These findings were published in JAMA Psychiatry.

People diagnosed with schizophrenia face a reduced life expectancy compared to the general population. This gap is estimated to be approximately fifteen years. The primary driver of this early mortality is not the psychiatric condition itself but rather cardiovascular disease. High rates of obesity and type 2 diabetes are common in this group. These physical health issues stem from a combination of lifestyle factors and genetic predispositions.

A major contributing factor to poor physical health is the treatment for the mental illness itself. Antipsychotic medications are essential for managing the symptoms of schizophrenia. However, they frequently cause severe side effects related to metabolism. Patients often experience rapid weight gain and disruptions in how their bodies process glucose.

Two specific medications, clozapine and olanzapine, are known to carry the highest risk for these metabolic problems. These drugs are classified as second-generation antipsychotics. Despite these risks, they remain vital tools for psychiatrists. Clozapine is often the only effective option for patients who do not respond to other treatments.

Doctors face a difficult dilemma when treating these patients. Switching a patient off clozapine to improve their physical health can lead to a relapse of psychosis. Consequently, physicians often attempt to manage the side effects with additional medications. Common strategies include prescribing metformin or topiramate to control weight and blood sugar.

Free daily newsletter

Unfortunately, these add-on treatments often provide only limited benefits. Patients might lose a small amount of weight, but it is rarely enough to reverse the risk of diabetes or heart disease. There is a pressing need for therapies that can powerfully counteract metabolic side effects without interfering with psychiatric care. This need drove the current research effort.

The study was led by Marie R. Sass from the Mental Health Center Copenhagen in Denmark. She worked alongside a large team of researchers from Danish institutions and the Zucker Hillside Hospital in New York. They sought to determine if newer diabetes drugs could offer a better solution. Specifically, they investigated a class of drugs known as glucagon-like peptide-1 receptor agonists, or GLP-1RAs.

Semaglutide is a well-known medication in this class. It mimics a hormone that regulates appetite and insulin secretion. Regulatory bodies have approved it for treating type 2 diabetes and obesity. The researchers hypothesized that it could protect patients with schizophrenia from the metabolic damage caused by their antipsychotic regimen.

The research team designed a rigorous experiment to test this theory. They conducted a multicenter, double-blind, randomized clinical trial. This design is considered the gold standard for medical research. It minimizes bias by ensuring neither the doctors nor the patients know who is receiving the real drug.

The trial included 73 adult participants. All participants had been diagnosed with a schizophrenia spectrum disorder. Each participant had started treatment with either clozapine or olanzapine within the previous five years. This criterion focused the study on the early stages of metabolic disruption.

The researchers screened these individuals for signs of blood sugar problems. Participants had to show evidence of prediabetes or early-stage diabetes to qualify. They were then randomly assigned to two groups. One group received a weekly injection of semaglutide, while the other received a placebo injection.

The trial lasted for 26 weeks. During this time, the researchers gradually increased the dose of semaglutide to a target of 1 milligram. This is a standard dose for diabetes management. The team monitored the participants closely for changes in health markers and side effects.

The primary goal was to measure changes in hemoglobin A1c levels. Hemoglobin A1c is a blood test that reflects average blood sugar levels over the past three months. It provides a more stable picture of metabolic health than a single daily glucose test. The researchers also tracked body weight and waist circumference.

The results showed a distinct advantage for the group receiving the medication. Semaglutide reduced hemoglobin A1c levels compared to the placebo. The magnitude of the improvement was clinically significant. This suggests a substantial reduction in the risk of developing full-blown diabetes.

The data revealed that 43 percent of the individuals treated with semaglutide achieved what doctors call “low-risk” blood sugar levels. In comparison, only 3 percent of the placebo group reached this healthy range. This stark difference highlights the drug’s efficacy. It effectively normalized glucose metabolism for nearly half of the treated patients.

Weight loss results were equally distinct. After adjusting for the effects of the placebo, the semaglutide group lost an average of 9.2 kilograms, or about 20 pounds. This physical change was accompanied by a reduction in waist size. The average reduction in waist circumference was approximately 7 centimeters.

The study also examined body composition in greater detail. The researchers found that the weight loss was primarily due to a reduction in fat mass. This is a positive outcome, as muscle loss can be a concern with rapid weight reduction. The reduction in total body fat suggests a genuine improvement in physical health.

Safety was a primary concern throughout the trial. The researchers needed to ensure that semaglutide would not interfere with the antipsychotic medications. They found that psychiatric symptoms did not worsen in the group taking semaglutide. Hospitalization rates for psychiatric reasons were low and similar in both groups.

Physical side effects were consistent with what is known about GLP-1 receptor agonists. The most common complaints were gastrointestinal issues. Nausea, vomiting, and constipation were reported more frequently in the semaglutide group. These side effects are typical for this class of drugs and often subside over time.

One participant in the semaglutide group died of sudden cardiac death shortly after the trial concluded. An autopsy was performed to investigate the cause. The medical examiners determined that the death was not related to the semaglutide treatment. Serious adverse events were otherwise balanced between the two groups.

The researchers also looked at secondary outcomes unrelated to weight. One finding involved nicotine use. Smoking rates are historically very high among people with schizophrenia. The study data suggested that semaglutide might reduce nicotine dependence.

Participants who smoked and took semaglutide had lower scores on a test measuring nicotine dependence compared to the placebo group. This aligns with emerging theories that GLP-1 drugs may influence reward pathways in the brain. It raises the possibility that these drugs could help treat addiction. However, the researchers noted this was an exploratory finding.

There were limitations to what the study could determine regarding other organs. The team did not see significant changes in liver function or cholesterol levels. This might be because the participants were relatively young and their metabolic problems were in the early stages. It is also possible that the 1 milligram dose was not high enough to alter lipid profiles significantly.

The dose used in this study is lower than the 2.4 milligram dose often prescribed specifically for weight loss in the general population. The researchers suggest that higher doses might yield even greater benefits. Longer trials would be necessary to confirm this. The 26-week duration was relatively short in the context of lifelong chronic illness.

The demographics of the study population also present a limitation. The majority of participants were White. This limits the ability to generalize the findings to other racial and ethnic groups who may have different metabolic risk profiles. Future studies will need to be more inclusive to ensure the treatment is effective for everyone.

Another challenge mentioned is the cost and accessibility of these medications. GLP-1 receptor agonists are currently expensive. This presents a barrier for many patients with severe mental illness who rely on public health systems. The authors argue that preventing diabetes and heart disease could save money in the long run.

The study, “Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders A Randomized Clinical Trial,” was authored by Marie R. Sass, Mette Kruse Klausen,Christine R. Schwarz, Line Rasmussen, Malte E. B. Giver, Malthe Hviid, Christoffer Schilling, Alexandra Zamorski,Andreas Jensen, Maria Gefke, Heidi Storgaard, Peter S. Oturai, Andreas Kjaer, Bolette Hartmann, Jens J. Holst, Claus T. Ekstrøm, Maj Vinberg,Christoph U. Correll, Tina Vilsbøll, and Anders Fink-Jensen.